- A Case Report of a Patient Carrying CYP2C9*3/4 Genotype with Extremely Low Warfarin Dose Requirement
-
Lee SY, Nam MH, Kim JS, Kim JW
- KMID: 1778371
- J Korean Med Sci.
- 2007 Jun;22(3):557-559.
- doi: 10.3346/jkms.2007.22.3.557
We report a case of intolerance to warfarin dosing due to impaired drug metabolism in a patient with CYP2C9*3/*4. A 73-yr-old woman with atrial fibrilation was taking warfarin. She attained... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of Femoral Vascular Closure Devices in Patients Treated with Anticoagulant, Abciximab or Thrombolytics during Percutaneous Endovascular Procedures
-
Kim HY, Choo SW, Roh HG, Han H, Kim SS, Lee JY, Park YR, Lee SH, Shin SW, Park KB, Do YS, Cho SK, Lee IH, Kim SM, Byun HS, Jeon P
- KMID: 753914
- Korean J Radiol.
- 2006 Mar;7(1):35-40.
- doi: 10.3348/kjr.2006.7.1.35
OBJECTIVE: This study assessed the outcomes of using vascular closure devices following percutaneous transfemoral endovascular procedures in the patients who were treated with heparin, abciximab or thrombolytics (urokinase or t-PA)... -
- CITED
-
- Close
- SHARE
-
- Close
- Heparin attenuated neutrophil infiltration but did not affect renal injury induced by ischemia reperfusion
-
Shin CS, Han JU, Kim JL, Schenarts , Traber LD, Hawkins H, Traber DL
- KMID: 699941
- Yonsei Med J.
- 1997 Jun;38(3):133-141.
- doi: 10.3349/ymj.1997.38.3.133
Although heparin is better known as an anticoagulant, it also has several anti-inflammatory effects. Heparin is known to inhibit neutrophil adhesion, chemotaxis and oxygen free radical production. In... -
- CITED
-
- Close
- SHARE
-
- Close
